- News Releases
Researchers find lower incidence of chronic damage to the kidney due to rejection and better overall kidney function at 5 years post transplant
ROCHESTER, Minn. — A new study from physicians at Mayo Clinic in Rochester, found there may be long-term benefits to simultaneous liver-kidney transplantation versus kidney transplantation alone. The study, “Decreased Chronic Cellular and Antibody-Mediated Injury in the Kidney Following Simultaneous Liver-Kidney Transplantation” published recently in the journal Kidney International. Among patients with high and low levels of donor-specific alloantibodies, the study showed those who received simultaneous liver-kidney transplants demonstrated a lower incidence of cellular and antibody-mediated rejection and chronic injury to the kidney, and demonstrated better overall kidney function five years post procedure.
Rejection of transplanted organs can occur within minutes (hyperacute rejection) or days to months (acute) after a transplant. In other cases, the damage takes place over a number of years and can lead to decreased kidney function and, potentially, rejection of the transplanted organ. This is known as chronic kidney injury. While past research has shown that patients who have a combined or simultaneous liver-kidney transplant can be protected from hyperacute and acute rejection, the recent Mayo Clinic study is the first to examine the potential long-term effects of simultaneous liver-kidney transplant and chronic kidney injury or function.
“We know that a healthy liver can reduce the levels of circulating donor-specific alloantibodies, which can lead to rejection of a transplanted organ in kidney transplant recipients,” says Timucin Taner, M.D., Ph.D., a transplant surgeon at Mayo Clinic. “The findings from this study indicate that these positive benefits of a healthy liver in simultaneous liver-kidney transplants may be long-standing and that the liver may have a protective role against cellular rejection, as well”
MEDIA CONTACT: Ginger Plumbo, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org.
Mayo Clinic physicians studied kidney biopsies from 68 consecutive liver-kidney transplant recipients, 14 with donor-specific alloantibodies and 54 with low or no donor-specific alloantibodies. These results were compared to biopsies from patients who had received a kidney transplant alone, with a comparable break down of high and low donor-specific alloantibodies.
Factors studied included the overall five-year patient and graft or transplant survival; the incidence of acute rejection and chronic kidney damage; and overall measures of kidney function. Findings indicate that, at five years post-transplant in patients with donor-specific alloantibodies, those who had a simultaneous liver-kidney transplant kidney transplant had a:
“This study is promising, because it demonstrates the power of a well-functioning liver allograft in modulating host immune responses and positively influencing long-term outcomes of the kidney transplant in simultaneous liver-kidney transplant recipients,” says Dr. Taner. “More work is needed to better understand how far this benefit extends beyond transplantation, as well as how immunosuppressive therapies impact these outcomes.”
April is Donate Life Month. More than 120,000 people are waiting for an organ transplant in the United States. Nearly 2,000 of those are children. Mayo Clinic has over 3,000 patients on the waiting list for an organ transplant. Every 10 minutes another name is added to the national waiting list. An average of 21 people die each day in the United States waiting for transplants that can't take place because of the shortage of donated organs.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or https://newsnetwork.mayoclinic.org/.